More tools:Markets·Screener·Research·Chat

Mirum Pharmaceuticals, Inc. Common Stock (MIRM) Financial Statements

Mirum Pharmaceuticals, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00MH7T2N6
XNAS · usd
99.77▲ 0.24 (0.24%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close99.53
Day's Range97.65 – 101.83
52-Week Range63.23 – 130.00
Volume638.1K
Avg Volume623.2K
Share Statistics
Shares Outstanding
Employees372
ExchangeXNAS
Listed2019-07-18
Share count as of July 31, 2026
Loading Income Statement…
Key questions about Mirum Pharmaceuticals, Inc. Common Stock (MIRM)
What is Mirum Pharmaceuticals, Inc. Common Stock's Market Cap?
Mirum Pharmaceuticals, Inc. Common Stock's Market Cap is $6.5B, based on as-reported figures from SEC (XBRL) filings.
What is Mirum Pharmaceuticals, Inc. Common Stock's Enterprise Value?
Mirum Pharmaceuticals, Inc. Common Stock's Enterprise Value is $6.0B, based on as-reported figures from SEC (XBRL) filings.
What is Mirum Pharmaceuticals, Inc. Common Stock's Price / Sales?
Mirum Pharmaceuticals, Inc. Common Stock's Price / Sales is 10.5×, based on as-reported figures from SEC (XBRL) filings.
What is Mirum Pharmaceuticals, Inc. Common Stock's EV / Revenue?
Mirum Pharmaceuticals, Inc. Common Stock's EV / Revenue is 9.8×, based on as-reported figures from SEC (XBRL) filings.
What is Mirum Pharmaceuticals, Inc. Common Stock's EV / EBITDA?
Mirum Pharmaceuticals, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Mirum Pharmaceuticals, Inc. Common Stock's Revenue (TTM)?
Mirum Pharmaceuticals, Inc. Common Stock's Revenue (TTM) is $618.1M, based on as-reported figures from SEC (XBRL) filings.
What is Mirum Pharmaceuticals, Inc. Common Stock's Net Income (TTM)?
Mirum Pharmaceuticals, Inc. Common Stock's Net Income (TTM) is -$860.2M, based on as-reported figures from SEC (XBRL) filings.
What is Mirum Pharmaceuticals, Inc. Common Stock's EBITDA?
Mirum Pharmaceuticals, Inc. Common Stock's EBITDA is -$808.0M, based on as-reported figures from SEC (XBRL) filings.
What is Mirum Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM)?
Mirum Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM) is -13.25, based on as-reported figures from SEC (XBRL) filings.
What is Mirum Pharmaceuticals, Inc. Common Stock's EBITDA Margin?
Mirum Pharmaceuticals, Inc. Common Stock's EBITDA Margin is -130.7%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Product sales, net
YoY growth+37.9%+43.3%+49.8%+47.2%
Operating expenses:
Cost of sales
Research and development
Acquired in-process research and development——
Selling, general and administrative
Total operating expenses
% of revenue124.1%593.8%103.1%98.0%
Loss from operations
% of revenue-24.1%-493.8%-3.1%2.0%
Other income (expense):
Interest income
Interest expense
Other (expense) income, net
Net loss before provision for income taxes
Net loss
% of revenue-38.1%-494.2%-3.8%2.2%
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)